Subjects:
Free Research Articles
Topics:
acute lymphocytic leukemia, chemotherapy regimen, imatinib mesylate

On page 3713 in the 11 June 2015 issue, there are errors in Table 1. The table does not distinguish between the respective doses and schedules for the drugs filgrastim and pegfilgrastim. Also, the schedule for the pre-SCT interphase treatment phase with the drug MTX reads “Days 1-8.” It should read “Days 1 and 8.” The corrected Table 1 is shown below. The errors have been corrected in the online version, which now differs from the print version.

Table 1

GRAAPH-2005 treatments

Treatment phasesDrugsDosesSchedules
Initial treatments    
 Prephase PDN 60 mg/m2/d po Day −7 to day −1 
 MTX 15 mg IT Between day −7 and day −4 
 Cycle 1 arm A VCR 2 mg/d IV Days 1, 8, 15, and 22 
 DXM 40 mg/d po Days 1-2, 8-9, 15-16, and 22-23 
 Imatinib 400 mg bid po Days 1-28 
 Filgrastim 5 μg/kg/d sc/IV From day 15 to PMN recovery 
 Cycle 1 arm B VCR 2 mg/d IV Day 4 and day 11 
 DXM 40 mg/d po Days 1-4 and 11-14 
 DXR 50 mg/m2/d CIV Day 4 
 CPM 300 mg/m2/12 h IV Day 1-3 
 Imatinib 400 mg bid po Day 1-14 
 Filgrastim or pegfilgrastim 5 μg/kg/d sc/IV (filgrastim) or 6 mg sc (pegfilgrastim) From day 15 to PMN recovery (filgrastim) or day 6 (pegfilgrastim) 
 Cycle 2 (both arms) MTX 1000 mg/m2/d CIV Day 1 
 Ara-C 3000 mg/m2/12 h IV Days 2-3 
 Imatinib 400 mg bid po Days 1-14 
 Filgrastim or pegfilgrastim 5 μg/kg/d sc/IV (filgrastim) or 6 mg sc (pegfilgrastim) From day 9 to PMN recovery (filgrastim) or day 6 (pegfilgrastim) 
 Pre-SCT interphase (n = 2) MTX 25 mg/m2/d po Days 1 and 8 
 6-MP 60 mg/m2/d po Days 1-14 
 Imatinib 300 mg bid po Days 1-14 
Further treatments for non-SCT patients    
 Cycles 3, 5, and 7 Identical to cycle 1 arm B, with reduced 300 mg imatinib bid from day 1 to day 14 
 Cycles 4, 6, and 8 Identical to cycle 2, with reduced 300 mg imatinib bid from day 1 to day 14 
 Monthly maintenance cycles Replaced at month 6 by a cycle 9 (like cycles 3, 5 and 7) and at month 12 by a cycle 10 (like cycles 4, 6, and 8) 
 PDN 200 mg/d po Days 1-5, months 1-12 
 VCR 2 mg/d IV Day 1, months 1-12 
 Imatinib 300 mg bid po Months 1-24 
Post–autologous SCT maintenance    
 Months 1, 3, 5... to 23 Imatinib 300 mg bid po For 1 mo 
 Months 2, 4, 6... to 24 MTX 25 mg/m2/wk po For 1 mo 
 6-MP 60 mg/m2/d po For 1 mo 
CNS treatments    
 CNS prophylaxis Triple IT* n = 1 Days 1, 8, and 15 of cycle 1 
 Triple IT n = 1 Day 9 of cycle 2 
 Triple IT n = 1 Day 1 of the 2 interphase cycles 
 If initial CNS involvement Triple IT n = 8 Between day −7 and day 21 of cycle 1 
 Triple IT n = 1 per wk thereafter For a total of 12 ITs 
 Cranial irradiation 15 Gy before SCT or 24 Gy after cycle 8 in non-SCT patients  
 Imatinib 300 mg bid po During cranial irradiation 
Treatment phasesDrugsDosesSchedules
Initial treatments    
 Prephase PDN 60 mg/m2/d po Day −7 to day −1 
 MTX 15 mg IT Between day −7 and day −4 
 Cycle 1 arm A VCR 2 mg/d IV Days 1, 8, 15, and 22 
 DXM 40 mg/d po Days 1-2, 8-9, 15-16, and 22-23 
 Imatinib 400 mg bid po Days 1-28 
 Filgrastim 5 μg/kg/d sc/IV From day 15 to PMN recovery 
 Cycle 1 arm B VCR 2 mg/d IV Day 4 and day 11 
 DXM 40 mg/d po Days 1-4 and 11-14 
 DXR 50 mg/m2/d CIV Day 4 
 CPM 300 mg/m2/12 h IV Day 1-3 
 Imatinib 400 mg bid po Day 1-14 
 Filgrastim or pegfilgrastim 5 μg/kg/d sc/IV (filgrastim) or 6 mg sc (pegfilgrastim) From day 15 to PMN recovery (filgrastim) or day 6 (pegfilgrastim) 
 Cycle 2 (both arms) MTX 1000 mg/m2/d CIV Day 1 
 Ara-C 3000 mg/m2/12 h IV Days 2-3 
 Imatinib 400 mg bid po Days 1-14 
 Filgrastim or pegfilgrastim 5 μg/kg/d sc/IV (filgrastim) or 6 mg sc (pegfilgrastim) From day 9 to PMN recovery (filgrastim) or day 6 (pegfilgrastim) 
 Pre-SCT interphase (n = 2) MTX 25 mg/m2/d po Days 1 and 8 
 6-MP 60 mg/m2/d po Days 1-14 
 Imatinib 300 mg bid po Days 1-14 
Further treatments for non-SCT patients    
 Cycles 3, 5, and 7 Identical to cycle 1 arm B, with reduced 300 mg imatinib bid from day 1 to day 14 
 Cycles 4, 6, and 8 Identical to cycle 2, with reduced 300 mg imatinib bid from day 1 to day 14 
 Monthly maintenance cycles Replaced at month 6 by a cycle 9 (like cycles 3, 5 and 7) and at month 12 by a cycle 10 (like cycles 4, 6, and 8) 
 PDN 200 mg/d po Days 1-5, months 1-12 
 VCR 2 mg/d IV Day 1, months 1-12 
 Imatinib 300 mg bid po Months 1-24 
Post–autologous SCT maintenance    
 Months 1, 3, 5... to 23 Imatinib 300 mg bid po For 1 mo 
 Months 2, 4, 6... to 24 MTX 25 mg/m2/wk po For 1 mo 
 6-MP 60 mg/m2/d po For 1 mo 
CNS treatments    
 CNS prophylaxis Triple IT* n = 1 Days 1, 8, and 15 of cycle 1 
 Triple IT n = 1 Day 9 of cycle 2 
 Triple IT n = 1 Day 1 of the 2 interphase cycles 
 If initial CNS involvement Triple IT n = 8 Between day −7 and day 21 of cycle 1 
 Triple IT n = 1 per wk thereafter For a total of 12 ITs 
 Cranial irradiation 15 Gy before SCT or 24 Gy after cycle 8 in non-SCT patients  
 Imatinib 300 mg bid po During cranial irradiation 

Ara-C, cytarabine; bid, twice daily; CIV, continuous IV; CNS, central nervous system; CPM, cyclophosphamide; DXM, dexamethasone; DXR, doxorubicin; IT, intrathecal; 6-MP, 6-mercaptopurine; MTX, methotrexate; PDN, prednisone; PMN, polymorphonuclear neutrophil; po, by mouth; sc, subcutaneously; VCR, vincristine.

*

Triple IT consisted of 15 mg MTX, 40 mg Ara-C, and 40 mg PDN.

View Large
© 2015 by The American Society of Hematology
2015
Sign in via your Institution